CERES BRAIN Therapeutics’ Post

Ceres Brain Therapeutics SAS is proud to announce that the FDA has granted rare Pediatric Designation from our leading asset, CBT101, for the treatment of Creatine Transporter Deficiency Syndrome (CTD). This opens the door to potentially receiving a Priority Review Voucher, a key step in accelerating the development of our innovative treatments. Stay tuned for more updates! We remind you that CTD is an X-linked gene disease resulting in severe intellectual deficiency, autistic syndrome and seizure due to lack of creatine in brain neurons. CBT101, is a prodrug of creatine that delivers creatine to brain neurons by following the nose-to-brain pathway after nasal administration. CBT101 demonstrated particularly strong efficacy in two different mice models of CTD, increasing brain plasticity, improving brain metabolism and restoring cognition. https://lnkd.in/e4ka-7uY